Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Humanigen Major Shareholders & Ownership History
Reporting Date Major Shareholder Name Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company Details
5/12/2023 BlackRock Inc. 1,025,320 $0.15M 0.0% +8.4% 0.861%
5/12/2023 UBS Group AG 322,732 $46K 0.0% +56.6% 0.271%
2/15/2023 Virtu Financial LLC 301,792 $36K 0.0% +225.9% 0.291%
2/13/2023 Renaissance Technologies LLC 1,491,771 $0.18M 0.0% +72.3% 1.439%
2/8/2023 UBS Group AG 206,151 $25K 0.0% +293.0% 0.199%
12/8/2022 Bank of New York Mellon Corp 620,733 $0.11M
Down 65k today
Nope. Bought more at .052.
New lows
You don’t want anyone to search your previous posts. As said before all have been 100% wrong. Stop the nonsense
Is Dale buying? He and other insiders can buy the company for pennies on the $? Remember their brilliant trading to sell above $17 PPS shortly before the EUA denial. Will they make a great investment today at 5 cents ?
You can’t even admit it was a bad decision? Denial and re directing can be a sickness. Can LENZ help?
Another great decision by ‘ management’
Doing the opposite would have been 100% correct.
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
https://finance.yahoo.com/news/humanigen-lenzilumab-being-studied-potential-160500519.html
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
https://finance.yahoo.com/news/humanigen-presents-promising-hematologic-data-160500864.html
Dead cat bounce of 12 million shares traded is .001. Unbelievable
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As a result of the below-reported resignations of three members of the board of directors (the “Board”) of Humanigen, Inc. (the “Company”), the Company notified The Nasdaq Stock Market of the Company’s non-compliance with each of Nasdaq Rule 5605(b)(1), which requires a Nasdaq-listed company to have a board of directors comprised of a majority of independent directors; and Nasdaq Rule 5605(c)(2), which requires a Nasdaq-listed company to have an audit committee of the board of directors comprised of at least three independent directors meeting the eligibility requirements of that Rule.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 18, 2023, John Hohneker resigned from the Board, and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect. The decisions of Dr. Hohneker, Ms. Buxton and Mr. Xie to resign were not the result of disagreements with Humanigen on any matter relating to Humanigen's operations, policies or practices.
Item 8.01 Other Events.
Corporate Update
has been unsuccessful in raising debt or equity financing in sufficient amounts and with acceptable terms to fund the Company’s operations going forward.
In light of these developments and the matters discussed above under Item 3.01, on July 21, 2023, the Company notified the Nasdaq Hearings Panel (the “Panel”) that it does not expect to be able to demonstrate compliance with all applicable criteria for listing on The Nasdaq Capital Market by August 21, 2023, including the $1.00 minimum bid price per share requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company received a letter on the evening of July 24, 2023 indicating that the Panel will delist the shares of the Company
The Company’s negotiations with a privately held biopharmaceutical company relating to a proposed business combination, as disclosed in the Company’s
Quarterly Report on Form 10-Q filed on May 15, 2023, have ended without execution of a definitive agreement. In addition, the Company has been
unsuccessful in its attempt to identify and complete another strategic or equity financing transaction in the first half of 2023 on terms sufficient to enable the
Company to regain compliance with applicable Nasdaq listing requirements within the extended compliance period of August 21, 2023. The Company further
from the Nasdaq Capital Market and trading in the Company shares will be suspended from Wednesday, July 26, 2023.
The shares will commence trading on the OTC Pink Market. The suspension from trading and delisting from the Nasdaq Capital Market likely would adversely
affect the liquidity of the Company’s common stock and its ability to raise additional capital.
In light of the above, and the Company’s limited cash and cash equivalents, the Company anticipates that it will not be able to continue as a going concern and
is exploring all restructuring options, which may include commencing a bankruptcy or other insolvency proceeding sometime in the third quarter of 2023. In
that regard, the Company is evaluating term sheets relating to potential sales of assets in a bankruptcy proceeding. Given the Company’s lack of liquidity, any
such bankruptcy filing may result in a complete or substantial loss of value for holders of our common stock.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
104
Cover Page Interactive Data File (embedded within Inline XBRL document).
Did Nasdaq strike again? We should have 27 more days to regain compliance.
‘No Durant and Dale did’. It’s their fault not the NASDQ.
LENZ patent is with 1,000,000,000,000,000,000 and they are looking to be acquired by Gilead for a trillion? You didn’t get this update from management?
I guess the shorts can cover under 6 cents. The squeeze
No wonder we have not heard from management’
Humanigen to weigh bankruptcy as shares delist from Nasdaq
Jul. 25, 2023 6:54 AM ETHumanigen, Inc. (HGEN)By: Dulan Lokuwithana, SA News Editor
No more Covid cures as this failed attempt has plummeted the PPS. No more!!!
We have seen this run to over $2.50!! Round 2 is up. Hoping for a AI merger
Easy
It’s called delusion..
You should be worried about the years of disgusting decline. Management needs to be held accountable.
Just follow the PPS as that’s all that’s matters. Everything else does not make sense and is the managements job to explain aka with shareholder update
Doesn’t look like the shorts are concerned. Let’s hope they are forced into a squeeze
Bingo !!
HGEN wants to run!! We need a reason!!!
IF management can deliver a response for shorts to cover and a squeeze to happen. So far the shorts have been brilliant betting against
We are at a market cap of 21 million with a PPS of 17 cents. Stop to EXCUSES
Because they suck!! They have destroyed shareholders with their over focus on COVID and their inabilities to make LENZ a house hold name. If all message board options dictated the PPS we would all be RICH. It DOES NOT. I called it as I see it and not cheering from the sidelines and justifying FAILURE!!
‘I think that management has amazing foresight’
Delusional and discredits your entire dream theories
Careful not to get run over. Good luck
Cause I’m a gambler and avg down on the thought we may get a reversal. Even a blind squirrel can find a nut.
I added today like an idiot
Once must admit these guys are garbage
Management failing us again
Close. News can move this
Yes. We should be oversold
Nice volume. Low OS